<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Neurol</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Neurol</journal-id>
<journal-id journal-id-type="publisher-id">Front. Neurol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Neurology</journal-title>
</journal-title-group>
<issn pub-type="epub">1664-2295</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30863356</article-id>
<article-id pub-id-type="pmc">6399128</article-id>
<article-id pub-id-type="doi">10.3389/fneur.2019.00119</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Neurology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Role of DNA Methylation and Adenosine in Ketogenic Diet for Pharmacoresistant Epilepsy: Focus on Epileptogenesis and Associated Comorbidities</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Fan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>He</surname>
<given-names>Xinghui</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Luan</surname>
<given-names>Guoming</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Tianfu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/524050/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Beijing Key Laboratory of Epilepsy Research, Department of Neurology, Beijing Institute for Brain Disorders, Sanbo Brain Hospital, Capital Medical University</institution>, <addr-line>Beijing</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Beijing Key Laboratory of Epilepsy Research, Department of Neurosurgery, Beijing Institute for Brain Disorders, Sanbo Brain Hospital, Capital Medical University</institution>, <addr-line>Beijing</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Fernando Cendes, Universidade Estadual de Campinas, Brazil</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Cherubino Di Lorenzo, Fondazione Don Carlo Gnocchi Onlus (IRCCS), Italy; Kette D. Valente, University of São Paulo, Brazil</p>
</fn>
<corresp id="c001">*Correspondence: Tianfu Li <email>tianfuli66@126.com</email></corresp>
<fn fn-type="other" id="fn001">
<p>This article was submitted to Epilepsy, a section of the journal Frontiers in Neurology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>26</day>
<month>2</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>10</volume>
<elocation-id>119</elocation-id>
<history>
<date date-type="received">
<day>05</day>
<month>10</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>29</day>
<month>1</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 Chen, He, Luan and Li.</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>Chen, He, Luan and Li</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Epilepsy is a neurological disorder characterized by a long term propensity to produce unprovoked seizures and by the associated comorbidities including neurological, cognitive, psychiatric, and impairment the quality of life. Despite the clinic availability of several novel antiepileptic drugs (AEDs) with different mechanisms of action, more than one-third of patients with epilepsy suffer with pharmacoresistant epilepsy. Until now, no AEDs have been proven to confer the efficacy in alteration of disease progression or inhibition of the development of epilepsy. The ketogenic diet, the high-fat, low-carbohydrate composition is an alternative metabolic therapy for epilepsy, especially for children with drug-resistant epilepsy. Recently clinical and experimental results demonstrate its efficacy in ameliorating both seizures and comorbidities associated with epilepsy, such as cognitive/psychiatric concerns for the patients with refractory epilepsy. Of importance, ketogenic diet demonstrates to be a promising disease-modifying or partial antiepileptogenesis therapy for epilepsy. The mechanisms of action of ketogenic diet in epilepsy have been revealed recently, such as epigenetic mechanism for increase the adenosine level in the brain and inhibition of DNA methylation. In the present review, we will focus on the mechanisms of ketogenic diet therapies underlying adenosine system in the prevention of epileptogenesis and disease modification. In addition, we will review the role of ketogenic diet therapy in comorbidities associated epilepsy and the underlying mechanisms of adenosine.</p>
</abstract>
<kwd-group>
<kwd>ketogenic diet</kwd>
<kwd>epilepsy</kwd>
<kwd>epileptogenesis</kwd>
<kwd>comorbidities</kwd>
<kwd>adenosine</kwd>
</kwd-group>
<counts>
<fig-count count="0"></fig-count>
<table-count count="0"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="110"></ref-count>
<page-count count="8"></page-count>
<word-count count="6832"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Possible implications of the ketogenic diet (KD), a high-fat, low-carbohydrate diet, have been demonstrated in neurological fields, for instance: cognitive decline and dementia (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>), Parkinson disease (<xref ref-type="bibr" rid="B3">3</xref>), multiple sclerosis and its cognitive complications (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>), migraine and cluster headache (<xref ref-type="bibr" rid="B6">6</xref>–<xref ref-type="bibr" rid="B8">8</xref>). Epilepsy is a chronic neurological disorder characterized by a long term propensity to produce unprovoked seizures and by the associated comorbidities including neurological, cognitive, psychiatric, and impairment the quality of life. (<xref ref-type="bibr" rid="B9">9</xref>). Despite several novel antiepileptic drugs (AEDs) move into clinic in recent years, pharmacotherapy is not effective in 30% of all cases, and up to 30 percent of patients with epilepsy remains refractory or drug resistant (<xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>), most of them are not suitable for resective operation and have to continue to suffer from uncontrolled recurrent seizures and the lower quality of life involved an extensive range of cognitive and psychiatric symptoms. However, current AEDs have been developed for antiictogenesis (inhibition of seizures) and not for antiepileptogenesis (prevention of epilepsy or disease-modification) (<xref ref-type="bibr" rid="B12">12</xref>). In addition, epilepsy has been regarded as prototype neuropsychiatric illness with interface of neurology and psychiatry, and treatment of comorbidity may autonomously ameliorate the efficacy for seizures inhibition and enhance the quality of life for patients with epilepsy (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>). KD was developed as a non-pharmacological treatment for epilepsy, and was regarded as a last resort of therapy for children with pharmacoresistant epilepsy. The efficacy of KD in the treatment of pharmacoresistant epilepsy suggests that the mechanisms of action in controlling seizures conferred by KD are different with that of conventional AEDs (<xref ref-type="bibr" rid="B15">15</xref>). Clinical and experimental results indicated that KD therapy is a promising disease-modifying or partial antiepileptogenesis treatment for pharmacoresistant epilepsy (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>). In addition, KD therapy provides effectiveness in ameliorating both seizures and comorbidities associated with epilepsy, such as cognitive/psychiatric concerns for the patients with pharmacoresistant epilepsy (<xref ref-type="bibr" rid="B18">18</xref>–<xref ref-type="bibr" rid="B21">21</xref>), and improving the quality of life (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>). The satisfactory efficacy in the treatment of patients with pharmacoresistant may offer the impetus to uncover novel mechanisms underlying the development of epilepsy and associated comorbidities. Therefore, in order to develop novel therapies aim to modify the development of epilepsy (disease modifcation) and associated comorbidities, there is a critical need to strengthen the extensive research for KD from bench to bedside and bedside to bench. The present review is indicted not to offer a comprehensive overview of all potential mechanisms, but to focus on the role of KD therapy in epileptogenensis, comorbidities associated with epilepsy, as well as the possible mechanisms underlying adenosine dysfunction.</p>
</sec>
<sec id="s2">
<title>Prevention or Modification of Epileptogenesis of the KD Therapy</title>
<p>The term epileptogenesis refers to a complex processes that happens prior to the initial epileptic seizure appears to translate the epileptic brain with higher propensity of recurrent seizures and processes that aggravate seizures to drug resistant (<xref ref-type="bibr" rid="B12">12</xref>), which involves alterations in expression and functions of receptors and ion channels, epigenetic alterations, inflammatory mechanisms, glial activation, and reorganization of neuronal circuitry (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B24">24</xref>). The true antiepileptogenic efficacy means prophylactic drug treatment in prevention of spontaneous recurrent seizures after a brain insult. The term disease modification refers to the therapy may modulate the intrinsic process of the disease even though it may not hamper the occurrence of a disease (<xref ref-type="bibr" rid="B12">12</xref>). The halt of development of epilepsy after initial diagnosis is defined as a therapy of disease modification (<xref ref-type="bibr" rid="B12">12</xref>). Until now, conventional AEDs offered efficacy only for inhibition of epileptic seizures and not for prophylaxis therapeutic intervention of epilepsy or modulation of the epilepsy development. Therefore, novel avenues for ideal therapies to hamper disease development of epilepsy are imperative (<xref ref-type="bibr" rid="B16">16</xref>).</p>
<p>The high-fat, low-carbohydrate KD has been regarded as a palliative therapy for pharmacoresistant epilepsy in children and adults. The 30% of children with pharmacoresistant epilepsy on the diet had more than 90% seizure reduction, and 52% of the children had more than 50% seizure reduction at 3 months (<xref ref-type="bibr" rid="B25">25</xref>). Even in adult patients with drug resistant epilepsy, 32% of those using KD attained the efficacy of seizure reduction more than 50% (<xref ref-type="bibr" rid="B26">26</xref>). Previous data on KD therapy in adolescents and adults indicted that up to 13% of patients with pharmacoresistant epilepsy were seizure-free and approximately two thirds of patients reduced seizure more than 50% (<xref ref-type="bibr" rid="B27">27</xref>). Currently, most of the KD therapy studies in epilepsy mainly focused on KD efficacy in seizure control, and no valid and well-designed clinical research to evaluate the efficacy of KD therapy on antiepileptogenesis or disease modification has been implemented (<xref ref-type="bibr" rid="B16">16</xref>). The emerging clinical findings indicated that KD can also provide antiepileptogenic and disease-modifying therapies in pharmacoresistant epilepsy (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B28">28</xref>). Some patients with KD therapy become long term seizure-free even after termination of KD therapy (<xref ref-type="bibr" rid="B17">17</xref>). The long term clinical efficacy in KD therapy for epilepsy over time might suggest the mechanism underlying disease-modification (<xref ref-type="bibr" rid="B29">29</xref>).</p>
<p>In addition, experimental research also indicated that KD therapy prevented disease progression in two different typical animal models of epilepsy induced by electrical kindling and chemicoconvulsants (<xref ref-type="bibr" rid="B16">16</xref>). In the pentylenetetrazole kindling mice model with consecutive injection of subconvulsant doses of pentylenetetrazole, KD but not a typical AEDs affords long-lasting protective efficacy (increased seizures threshold) against epileptic seizures caused by pentylenetetrazole even after termination of KD. This kindling model is an ideal animal model of epileptogenesis and has been extensively evaluated to study the pathomechanisms underlying the epileptogenic process (<xref ref-type="bibr" rid="B16">16</xref>). Therefore, the lasting outcomes in this kindling paradigms extensively used to evaluate the efficacy of the inherent capacity of antiepileptogenic therapy are likely to consistent with an antiepileptogenic or disease modification effect (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B29">29</xref>, <xref ref-type="bibr" rid="B30">30</xref>). In rats post-status epilepticus model of temporal lobe epilepsy evoked by pilocarpine, animals on the control diet displayed seizures progressed in severity and frequency, while animals on the KD diet displayed the epileptic seizures with severity and frequency significantly decreased (<xref ref-type="bibr" rid="B16">16</xref>). Of importance, reduction of seizures in the model maintained even after the diet reversal. Post-status epilepticus model of temporal lobe epilepsy have been extensively implanted to explore the novel AEDs with potential disease modifications, which is characterized by an first brain lesion, a dormant period, reactive astrogliosis in hippocampus and alteration of brain networks resulting in recurrent spontaneous seizures (<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B31">31</xref>). The results in the study highly indicated the KD offered a role in disease modification or partial antiepileptogenesis in a typical model of temporal lobe epilepsy (<xref ref-type="bibr" rid="B16">16</xref>).</p>
<p>Recent evidence demonstrated that KD treatment also confers antiepileptogenesis efficacy in genetic models of epilepsy with kcna1-null mutant mice (<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>). Kcna1-null mutant mice model occupied with several characteristics, such as early onset epilepsy with a severe seizure phenotype with myoclonic and generalized tonic–clonic seizures, resistant to traditional AEDs, cognitively impaired, cardiac arrhythmias and sudden death (<xref ref-type="bibr" rid="B33">33</xref>). It is an ideal model to study the epileptogenesis or disease modification, because the mice in the model experienced several kinds of temporal lobe epilepsy syndromes, and gradually progressed into terminal events associated with human sudden unexpected death in epilepsy (<xref ref-type="bibr" rid="B33">33</xref>–<xref ref-type="bibr" rid="B38">38</xref>). KD therapy demonstrated to retard the disease development, postpone the advent of catastrophic seizures, and to increase the life span by 47% in this model of progressive epilepsy (<xref ref-type="bibr" rid="B33">33</xref>).</p>
<p>However, there exist controversies on whether KD therapy has the role of antiepileptogenesis or disease modification. In the post-traumatic epilepsy model, a good model to test antiepileptogenic therapies (<xref ref-type="bibr" rid="B39">39</xref>), no evidence for KD-induced antiepileptogenesis was demonstrated (<xref ref-type="bibr" rid="B40">40</xref>). In rats post-status epilepticus model of temporal lobe epilepsy induced by pilocarpine, another commonly used model to verify disease modification or epileptogenesis (<xref ref-type="bibr" rid="B12">12</xref>), KD therapy did not demonstrated to halt the clinical course of epilepsy development after status epilepticus induced by an initial lithium-pilocarpine administration (<xref ref-type="bibr" rid="B41">41</xref>).</p>
<p>In addition, the adverse effects of the KD had been reported in extensive studies (<xref ref-type="bibr" rid="B42">42</xref>). The chief adverse effects were gastrointestinal symptoms, such as diarrhea, obstipation, vomiting (<xref ref-type="bibr" rid="B43">43</xref>–<xref ref-type="bibr" rid="B46">46</xref>) and weight down (<xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B46">46</xref>). Other adverse effects were also addressed, such as abdominal pain, renal stones, gallstones, infectious disease (pneumonia and sepsis), acute pancreatitis, hypercholesterolaemia, dropped bone matrix density, fatty liver, tachycardia, nephrocalcinosis, status epilepticus, acidosis, dehydration, prolonged of hospitalization, hunger and any infection of the respiratory tract (<xref ref-type="bibr" rid="B42">42</xref>).</p>
</sec>
<sec id="s3">
<title>Adenosine-Dependent Epigenetic Mechanism Involving the Disease Modification Therapy of KD</title>
<p>Extensive experimental and clinical evidence demonstrated that disruption of glia-derived adenosine system as one of the important mechanism subserved the development of epilepsy (<xref ref-type="bibr" rid="B47">47</xref>), and therapeutic adenosine augmentation exerts anticonvulsant and seizure terminating efficacy (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B47">47</xref>–<xref ref-type="bibr" rid="B53">53</xref>), mediated by both receptor-dependent and receptor–independent pathways (<xref ref-type="bibr" rid="B54">54</xref>). Antiictogenic effects (anticonvulsant effects) of adenosine are through adenosine receptor-dependent pathway, mainly acting via adenosine A1 receptors (A1R) (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B48">48</xref>, <xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B55">55</xref>–<xref ref-type="bibr" rid="B57">57</xref>). Acting through presynaptic A1R, adenosine may regulate multiple neurotransmitters releasing, and the most important inhibitory actions base on the glutamatergic system in the central nervous system (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B58">58</xref>). On the other hand, acting through post-synaptic A1R, adenosine has been proved to hyperpolarize the synaptic potentials in post-synaptic neurons and boost NMDA receptor inhibition via activation of K<sup>+</sup> channels (<xref ref-type="bibr" rid="B59">59</xref>). Our previous study demonstrated that KD increased the level of adenosine in the brain and exerted anticonvulsant effects via A1R (<xref ref-type="bibr" rid="B15">15</xref>).</p>
<p>Apart from its receptor-dependent efficacy, adenosine has been indicated to play a crucial role in modulation of DNA methylation homeostasis in receptor-independent effects (<xref ref-type="bibr" rid="B51">51</xref>, <xref ref-type="bibr" rid="B54">54</xref>, <xref ref-type="bibr" rid="B60">60</xref>). Adenosine is regarded as a mandatory end product of S-adenosylmethionine dependent transmethylation reactions (<xref ref-type="bibr" rid="B60">60</xref>–<xref ref-type="bibr" rid="B62">62</xref>). Upregulated adenosine kinase expression or deficiency of adenosine drives an increase in the transmethylation pathway leading to hypermethylated DNA, which is potentially implicated in epileptogenesis. Deficiency of adenosine and DNA hypermethylation develop into a vicious circle associated with in the onset of epileptogenesis, spontaneous seizures, progression of epilepsy and chronic pharmacoresistant epielpsy (<xref ref-type="bibr" rid="B60">60</xref>). Therefore, to restore the adenosine level or DNA methylation in epilepsy might be the novel and promising therapeutic target (<xref ref-type="bibr" rid="B62">62</xref>). Studies have demonstrated that focal augmentation of adenosine remarkably down-regulate DNA methylation in post-status epilepticus model of temporal lobe epilepsy (<xref ref-type="bibr" rid="B16">16</xref>). Therefore, adenosine and DNA methylation might be highlighted as emerging antiepileptogenic or disease-modification agents for epilepsy therapy (<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B62">62</xref>, <xref ref-type="bibr" rid="B63">63</xref>).</p>
<p>DNA methylation has been proved to exert high fidelity modulation of gene expression in brain and play an important role in the pathogenic mechanisms of onset of epileptogenesis and development of epilepsy. Therefore, intervention of DNA methylation is regarded as a reasonable prophylaxis therapy for epilepsy in view of the fact that it acts on directly the predominant pathway that initiates the mutiple downstream cellular and molecular events mediating epileptogenesis (<xref ref-type="bibr" rid="B62">62</xref>). Global DNA hypermethylation has been demonstrated in patients with temporal lobe epilepsy and rats post-status epilepticus model of temporal lobe epilepsy (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B51">51</xref>, <xref ref-type="bibr" rid="B61">61</xref>, <xref ref-type="bibr" rid="B62">62</xref>). Adenosine exerts a crucial role as an endogenous regulator of DNA methyltransferases activity. In recent study, KD therapy has been indicted to prevent disease progression via increased adenosine and decreased DNA methylation. Of note, down-regulation of DNA methylation by KD therapy maintained after diet discontinuation (<xref ref-type="bibr" rid="B16">16</xref>). Based on this premise, it is likely that the KD treatment plays its antiepileptogenic efficacy via an adenosine-dependent DNA methylation modulation (<xref ref-type="bibr" rid="B32">32</xref>).</p>
</sec>
<sec id="s4">
<title>Comorbidities Associated With Epilepsy</title>
<p>The term comorbidities have been defined as “any additional distinct clinical entity” (<xref ref-type="bibr" rid="B64">64</xref>, <xref ref-type="bibr" rid="B65">65</xref>). Several different kinds of comorbidities, such as cognitive comorbidities, psychiatric comorbidities and neurological comorbidities, exist in epilepsy (<xref ref-type="bibr" rid="B66">66</xref>). Psychiatric and neurological comorbidities are relatively frequent in epilepsy (<xref ref-type="bibr" rid="B67">67</xref>), affecting on average, 30–50% of patients (<xref ref-type="bibr" rid="B68">68</xref>). Currently, the goals of therapy for patients with epilepsy are not limited to reach the aim of seizure free, but must also the improvement of comorbidities associated with epilepsy, including neurological, psychiatric and cognitive comorbidities. Cognitive comorbidities include memory, attention, executive dysfunction, etc. Learning is one cognitive issue or a consequence and learning problems that lead to an major obstacle to get educational and professional success (<xref ref-type="bibr" rid="B66">66</xref>); Psychiatric comorbidities refer to behavior and mood problems, such as bipolar disorder, attention deficit hyperactivity disorder (ADHD), depression, anxiety disorders and autism (<xref ref-type="bibr" rid="B66">66</xref>). Neurological comorbidities are migraine headache (<xref ref-type="bibr" rid="B69">69</xref>), sleep disorders, such as sleep apnea, insomnia, restless legs syndrome, and the parasomnias (<xref ref-type="bibr" rid="B70">70</xref>), pain (neuropathic pain, fibromyalgia, chronic pain) and other (asthma, diabetes, and high blood pressure) (<xref ref-type="bibr" rid="B71">71</xref>). The comorbidities are frequent seen in patients with epilepsy, and can deteriorate quality of life further than seizures themselves do (<xref ref-type="bibr" rid="B18">18</xref>). Currently, the bidirectional relation between epilepsy and associated comorbidities has been paid much more attentions (<xref ref-type="bibr" rid="B72">72</xref>–<xref ref-type="bibr" rid="B76">76</xref>). Research upon the overlap of psychiatric and neurologic symptoms from a pathophysiologic and phenomenologic perspective is becoming a hot topic in epilepsy. The comorbidities associated with epilepsy are attributable to recurrent seizures and medications. In fact, the utmost recent data demonstrate that some neurocognitive and psychological comorbidities as well as structural brain changes predate the onset of seizures, with the early cognitive compromise being further magnified by the onset of epileptogenesis, and later on, by the chronicity of seizures (<xref ref-type="bibr" rid="B77">77</xref>–<xref ref-type="bibr" rid="B79">79</xref>). Therefore, the comorbidities need to be addressed in an early stage of the illness as they have a profound worse influence on the quality of life and complicate the therapeutic management of epilepsy (<xref ref-type="bibr" rid="B66">66</xref>). Base on this premise, it is crucial that therapy for epilepsy should aim at both seizures and comorbidities associated with epilepsy, because improving the lives of persons with epilepsy rely more on addressing comorbidities than seizures themselves (<xref ref-type="bibr" rid="B80">80</xref>, <xref ref-type="bibr" rid="B81">81</xref>).</p>
<p>Even though the KD therapy has been proved to be efficacy in inhibition of seizures in patients with pharmacoresistant epilepsy, much more attention is needed to comorbidities and clinical advantages of KD. Recent study demonstrated that KD therapy afford a beneficial contribution on behavioral and cognitive function in children and adolescents with pharmacoreisistant epilepsy (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B82">82</xref>, <xref ref-type="bibr" rid="B83">83</xref>). On the other hand, studies with objective neuropsychiatric tests demonstrated that KD therapy afford benefits on alertness without amelioration in global cognition (<xref ref-type="bibr" rid="B20">20</xref>). KD therapy provided cognitive improvements in patients with pharmacoreisistant epilepsy, although it is unclear if this is an independent efficacy of the diet (<xref ref-type="bibr" rid="B84">84</xref>). More specifically, an improvement is observed in mood, sustained attention, and social interaction. This activation of mood and cognition was not asssociated with the decrease of seizure frequency and correlates with the prominent efficacy of the KD (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B84">84</xref>), and appeared no relation to AEDs diminution, age when KD therapy is initiated, type of KD, and sleep amelioration (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>). In consistent with the effects of KD to control seizure and improve cognition in patients with pharmacoreisistant epilepsy, several lines of experimental research also demonstrated the neuroprotective efficacy on cognition (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B85">85</xref>, <xref ref-type="bibr" rid="B86">86</xref>). For the status of KD therapy in psychiatric comorbidities associated epilepsy, such as depression or bipolar disorder, although currently there is no long-term, prospective, randomized, placebo-controlled crossover dietary clinical trial (<xref ref-type="bibr" rid="B87">87</xref>), KD has been regarded as a novel frontier therapy for mood disorder, particularly in therapy with drug resistant mood disorder (<xref ref-type="bibr" rid="B88">88</xref>).</p>
<p>KD therapy has a long been used in children with pharmacoresistant epilepsy. However, overall distinct role of KD in comorbididties associated with epilepsy, especially psychiatric comorbididties is unclear. The impact of KD in psychiatric disorders is speculative. There is no solid evidence to corroborate this statement. Currently, there is inadequate evidence for the administration of KD in psychiatric comorbidities associated with epilepsy including behavior and mood problems, such as attention deficit disorder, bipolar disorder, depression, anxiety disorders, schizophrenia, autism spectrum disorder, and combinations of these conditions (<xref ref-type="bibr" rid="B87">87</xref>). So far, KD therapy is still not a recommended treatment option for the psychiatric disorders.</p>
</sec>
<sec id="s5">
<title>Adenosine Dysfunction in Comorbidities Associated With Epilepsy</title>
<p>For the cognitive comorbidities, extensive clinical and experimental study has been proved that adenosine plays an important role in controlling inflammation inhibiting seizures (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B47">47</xref>–<xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B53">53</xref>, <xref ref-type="bibr" rid="B55">55</xref>, <xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B89">89</xref>), and regaining cognitive function when cognition is afflicted secondary to epilepsy (<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B52">52</xref>, <xref ref-type="bibr" rid="B53">53</xref>, <xref ref-type="bibr" rid="B60">60</xref>). Adenosine impacts cognition processes via action on adenosine receptor A2A (A2AR) signaling pathway and regulation of neurotransmitters including glutamatergic, dopaminergic, GABAergic, and BDNF (<xref ref-type="bibr" rid="B90">90</xref>). The astrocytic A2AR might play a prominent role in interacts with glutamate transporter-1 and thereby regulates astroglial glutamate uptake. Therefore, malfunction of A2AR in astrocytes, by moduating glutamate transporter-1activity, initiates an astrocyte-to-neuron wave of communication causing disruption of glutamate system and cognitive impairment (<xref ref-type="bibr" rid="B91">91</xref>). Increasing the adenosine level in the brain via pharmacologic inhibition of the key enzyme of adenosine clearance, or intrastriatal implants of engineered adenosine-releasing cells can improve cognitive function (<xref ref-type="bibr" rid="B92">92</xref>). KD therapy has been proved to increase the adenosine level in the brain (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>), and KD therapy has been demonstrated to afford an improvement of cognitive activation in the patients with epilepsy (<xref ref-type="bibr" rid="B19">19</xref>). Based on the evidence above, it is strongly suggested that KD therapy ameliorated the cognition deficit though augmentation of the adenosine in the brain, which might be highly regarded as an ideal method for the therapy of cognitive comorbidities associated with epilepsy.</p>
<p>Depression is the common psychiatric comorbidities in patients with epilepsy (<xref ref-type="bibr" rid="B93">93</xref>). A1R signaling pathway in astrocytes has been demonstrated to be necessary in decreasing depressive-like behaviors secondary to sleep deprivation in mice (<xref ref-type="bibr" rid="B90">90</xref>), which indicated the activation of adenosine signaling triggered by sleep deprivation contributes to inhibition of depression (<xref ref-type="bibr" rid="B94">94</xref>). S-adenosylhomocysteine, a precursor of adenosine, has been found to be efficacy for the patients with treatment-resistant depressive disorder (<xref ref-type="bibr" rid="B95">95</xref>). The common clinical antidepressive treatment, such as acupuncture (<xref ref-type="bibr" rid="B96">96</xref>, <xref ref-type="bibr" rid="B97">97</xref>) and deep brain stimulation (<xref ref-type="bibr" rid="B98">98</xref>) has been indicated via increasing of adenosine and activation of A1R in the brain (<xref ref-type="bibr" rid="B99">99</xref>–<xref ref-type="bibr" rid="B101">101</xref>). KD therapy, the adenosine augmentation approach (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>), has been demonstrated to be effective in inhibition of depression (<xref ref-type="bibr" rid="B87">87</xref>). Therefore, it is suggested that one of the mechanisms underlying the KD therapy for depression via A1R. KD therapy might represent a novel strategy for the therapy of psychiatric comorbidities associated epilepsy.</p>
<p>Sleep disorders is the common neurologic comorbidities associated with epilepsy (<xref ref-type="bibr" rid="B70">70</xref>). Extensive studies have demonstrated that adenosine plays a crucial role in modulation of sleep homeostasis (<xref ref-type="bibr" rid="B90">90</xref>, <xref ref-type="bibr" rid="B102">102</xref>, <xref ref-type="bibr" rid="B103">103</xref>). Adenosine receptors A1R and A2AR have been demonstrated to play an important role in sleep modulation (<xref ref-type="bibr" rid="B90">90</xref>). A1R agonists promote sleep (<xref ref-type="bibr" rid="B104">104</xref>), while A1R antagonists inhibit sleep (<xref ref-type="bibr" rid="B105">105</xref>), via basal forebrain mediated mechanisms, respectively. A2AR agonist also has been demonstrated to promote sleep (<xref ref-type="bibr" rid="B106">106</xref>), via activation of cells of the leptomeninges or nucleus accumbens to reinforce the neuronal activity in ventrolateral preoptic region (<xref ref-type="bibr" rid="B107">107</xref>). This effect of sleep regulation was not found in A2AR-deficient mice (<xref ref-type="bibr" rid="B108">108</xref>). Inhibition of the A2AR in the shell of the nucleus accumbens (<xref ref-type="bibr" rid="B90">90</xref>, <xref ref-type="bibr" rid="B109">109</xref>) has been reputed the potential mechanism of the arousal effects of caffeine (non-selective antagonist of A1R and A2AR).</p>
<p>Ii is well-accepted that of upregulation of adenosine (increasing adenosine level or activation of adenosine receptors) promote sleep and downregulation of adenosine (decrease adenosine level or inactivation of adenosine receptors) induce wakefulness (<xref ref-type="bibr" rid="B90">90</xref>). It is hypothesized that a decreased adenosine tone uniformly forms the base for both epilepsy and sleep disruption (<xref ref-type="bibr" rid="B90">90</xref>). However, recent study found a lineal association of regionally distinguishable dichotomous levels of adenosine in one model represent both epilepsy and comorbid sleep disorders (<xref ref-type="bibr" rid="B110">110</xref>). In the model, adenosine level was decreased in the dorsal hippocampus contributing to seizure threshold diminution, while adenosine level was increased in the lateral hypothalamus leading to chronic partial sleep deprivation. To clarify the specific brain regional alterations in adenosine tone in patients underlies both epilepsy and sleep disorder is important for the targeted therapy in the future.</p>
</sec>
<sec id="s6">
<title>Author Contributions</title>
<p>The overall review design was conceived and supervised by TL. FC, XH, and GL helped in the writing different parts of the review. All authors read and approved the final manuscript.</p>
<sec>
<title>Conflict of Interest Statement</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</sec>
</body>
<back>
<ack>
<p>This Project was supported by the Grant from the National Key Research and Development Program of China (NO. 2016YFC0904401), the Grant from the BIBD-PXM2013_014226_07_000084, National Natural Science Foundation of China (81571275).</p>
</ack>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krikorian</surname><given-names>R</given-names></name><name><surname>Shidler</surname><given-names>MD</given-names></name><name><surname>Dangelo</surname><given-names>K</given-names></name><name><surname>Couch</surname><given-names>SC</given-names></name><name><surname>Benoit</surname><given-names>SC</given-names></name><name><surname>Clegg</surname><given-names>DJ</given-names></name></person-group>. <article-title>Dietary ketosis enhances memory in mild cognitive impairment</article-title>. <source/>Neurobiol Aging (<year>2012</year>) <volume>33</volume>:<fpage>419</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2010.10.006</pub-id><pub-id pub-id-type="pmid">21130529</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henderson</surname><given-names>ST</given-names></name><name><surname>Vogel</surname><given-names>JL</given-names></name><name><surname>Barr</surname><given-names>LJ</given-names></name><name><surname>Garvin</surname><given-names>F</given-names></name><name><surname>Jones</surname><given-names>JJ</given-names></name><name><surname>Costantini</surname><given-names>LC</given-names></name></person-group>. <article-title>Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial</article-title>. <source/>Nutr Metab. (<year>2009</year>) <volume>6</volume>:<fpage>31</fpage>. <pub-id pub-id-type="doi">10.1186/1743-7075-6-31</pub-id><pub-id pub-id-type="pmid">19664276</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanitallie</surname><given-names>TB</given-names></name><name><surname>Nonas</surname><given-names>C</given-names></name><name><surname>Di Rocco</surname><given-names>A</given-names></name><name><surname>Boyar</surname><given-names>K</given-names></name><name><surname>Hyams</surname><given-names>K</given-names></name><name><surname>Heymsfield</surname><given-names>SB</given-names></name></person-group>. <article-title>Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study</article-title>. <source/>Neurology (<year>2005</year>) <volume>64</volume>:<fpage>728</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1212/01.WNL.0000152046.11390.45</pub-id><pub-id pub-id-type="pmid">15728303</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Storoni</surname><given-names>M</given-names></name><name><surname>Plant</surname><given-names>GT</given-names></name></person-group>. <article-title>The therapeutic potential of the ketogenic diet in treating progressive multiple sclerosis</article-title>. <source/>Mult Scler Int. (<year>2015</year>) <volume>2015</volume>:<fpage>681289</fpage>. <pub-id pub-id-type="doi">10.1155/2015/681289</pub-id><pub-id pub-id-type="pmid">26839705</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francis</surname><given-names>HM</given-names></name><name><surname>Stevenson</surname><given-names>RJ</given-names></name></person-group>. <article-title>Potential for diet to prevent and remediate cognitive deficits in neurological disorders</article-title>. <source/>Nutr Rev. (<year>2018</year>) <volume>76</volume>:<fpage>204</fpage>–<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1093/nutrit/nux073</pub-id><pub-id pub-id-type="pmid">29346658</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Lorenzo</surname><given-names>C</given-names></name><name><surname>Curra</surname><given-names>A</given-names></name><name><surname>Sirianni</surname><given-names>G</given-names></name><name><surname>Coppola</surname><given-names>G</given-names></name><name><surname>Bracaglia</surname><given-names>M</given-names></name><name><surname>Cardillo</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Diet transiently improves migraine in two twin sisters: possible role of ketogenesis?</article-title>
<source/>Funct Neurol. (<year>2013</year>) <volume>28</volume>:<fpage>305</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.11138/FNeur/2013.28.4.305.</pub-id><pub-id pub-id-type="pmid">24598400</pub-id></mixed-citation>
</ref>
<ref id="B7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Lorenzo</surname><given-names>C</given-names></name><name><surname>Coppola</surname><given-names>G</given-names></name><name><surname>Sirianni</surname><given-names>G</given-names></name><name><surname>Di Lorenzo</surname><given-names>G</given-names></name><name><surname>Bracaglia</surname><given-names>M</given-names></name><name><surname>Di Lenola</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Migraine improvement during short lasting ketogenesis: a proof-of-concept study</article-title>. <source/>Eur J Neurol. (<year>2015</year>) <volume>22</volume>:<fpage>170</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/ene.12550</pub-id><pub-id pub-id-type="pmid">25156013</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Lorenzo</surname><given-names>C</given-names></name><name><surname>Coppola</surname><given-names>G</given-names></name><name><surname>Di Lenola</surname><given-names>D</given-names></name><name><surname>Evangelista</surname><given-names>M</given-names></name><name><surname>Sirianni</surname><given-names>G</given-names></name><name><surname>Rossi</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Efficacy of modified atkins ketogenic diet in chronic cluster headache: an open-label, single-arm, clinical trial</article-title>. <source/>Front Neurol. (<year>2018</year>) <volume>9</volume>:<fpage>64</fpage>. <pub-id pub-id-type="doi">10.3389/fneur.2018.00064</pub-id><pub-id pub-id-type="pmid">29483892</pub-id></mixed-citation>
</ref>
<ref id="B9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>RS</given-names></name><name><surname>van Emde</surname><given-names>BW</given-names></name><name><surname>Blume</surname><given-names>W</given-names></name><name><surname>Elger</surname><given-names>C</given-names></name><name><surname>Genton</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE)</article-title>. <source/>Epilepsia (<year>2005</year>) <volume>46</volume>:<fpage>470</fpage>–<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1111/j.0013-9580.2005.66104.x</pub-id><pub-id pub-id-type="pmid">15816939</pub-id></mixed-citation>
</ref>
<ref id="B10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Brodie</surname><given-names>MJ</given-names></name><name><surname>Liew</surname><given-names>D</given-names></name><name><surname>Kwan</surname><given-names>P</given-names></name></person-group>. <article-title>Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study</article-title>. <source/>JAMA Neurol. (<year>2018</year>) <volume>75</volume>:<fpage>279</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1001/jamaneurol.2017.3949</pub-id><pub-id pub-id-type="pmid">29279892</pub-id></mixed-citation>
</ref>
<ref id="B11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwan</surname><given-names>P</given-names></name><name><surname>Brodie</surname><given-names>MJ</given-names></name></person-group>. <article-title>Early identification of refractory epilepsy</article-title>. <source/>N Engl J Med. (<year>2000</year>) <volume>342</volume>:<fpage>314</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM200002033420503</pub-id><pub-id pub-id-type="pmid">10660394</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loscher</surname><given-names>W</given-names></name><name><surname>Brandt</surname><given-names>C</given-names></name></person-group>. <article-title>Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research</article-title>. <source/>Pharmacol Rev. (<year>2010</year>) <volume>62</volume>:<fpage>668</fpage>–<lpage>700</lpage>. <pub-id pub-id-type="doi">10.1124/pr.110.003046</pub-id><pub-id pub-id-type="pmid">21079040</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salpekar</surname><given-names>JA</given-names></name><name><surname>Mishra</surname><given-names>G</given-names></name><name><surname>Hauptman</surname><given-names>AJ</given-names></name></person-group>. <article-title>Key issues in addressing the comorbidity of depression and pediatric epilepsy</article-title>. <source/>Epilepsy Behav. (<year>2015</year>) <volume>46</volume>:<fpage>12</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.yebeh.2015.02.036</pub-id><pub-id pub-id-type="pmid">25863941</pub-id></mixed-citation>
</ref>
<ref id="B14">
<label>14.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhen</surname><given-names>XH</given-names></name><name><surname>Quan</surname><given-names>YC</given-names></name><name><surname>Jiang</surname><given-names>HY</given-names></name><name><surname>Wen</surname><given-names>ZS</given-names></name><name><surname>Qu</surname><given-names>YL</given-names></name><name><surname>Guan</surname><given-names>LP</given-names></name></person-group>. <article-title>Fucosterol, a sterol extracted from Sargassum fusiforme, shows antidepressant and anticonvulsant effects</article-title>. <source/>Eur J Pharmacol. (<year>2015</year>) <volume>768</volume>:<fpage>131</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2015.10.041</pub-id><pub-id pub-id-type="pmid">26515446</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masino</surname><given-names>SA</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Theofilas</surname><given-names>P</given-names></name><name><surname>Sandau</surname><given-names>US</given-names></name><name><surname>Ruskin</surname><given-names>DN</given-names></name><name><surname>Fredholm</surname><given-names>BB</given-names></name><etal></etal></person-group>
<article-title>A ketogenic diet suppresses seizures in mice through adenosine A(1) receptors</article-title>. <source/>J Clin Invest. (<year>2011</year>) <volume>121</volume>:<fpage>2679</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1172/JCI57813</pub-id><pub-id pub-id-type="pmid">21701065</pub-id></mixed-citation>
</ref>
<ref id="B16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lusardi</surname><given-names>TA</given-names></name><name><surname>Akula</surname><given-names>KK</given-names></name><name><surname>Coffman</surname><given-names>SQ</given-names></name><name><surname>Ruskin</surname><given-names>DN</given-names></name><name><surname>Masino</surname><given-names>SA</given-names></name><name><surname>Boison</surname><given-names>D</given-names></name></person-group>. <article-title>Ketogenic diet prevents epileptogenesis and disease progression in adult mice and rats</article-title>. <source/>Neuropharmacology (<year>2015</year>) <volume>99</volume>:<fpage>500</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.08.007</pub-id><pub-id pub-id-type="pmid">26256422</pub-id></mixed-citation>
</ref>
<ref id="B17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caraballo</surname><given-names>R</given-names></name><name><surname>Vaccarezza</surname><given-names>M</given-names></name><name><surname>Cersosimo</surname><given-names>R</given-names></name><name><surname>Rios</surname><given-names>V</given-names></name><name><surname>Soraru</surname><given-names>A</given-names></name><name><surname>Arroyo</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Long-term follow-up of the ketogenic diet for refractory epilepsy: multicenter argentinean experience in 216 pediatric patients</article-title>. <source/>Seizure (<year>2011</year>) <volume>20</volume>:<fpage>640</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.seizure.2011.06.009</pub-id><pub-id pub-id-type="pmid">21763159</pub-id></mixed-citation>
</ref>
<ref id="B18">
<label>18.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nickels</surname><given-names>KC</given-names></name><name><surname>Zaccariello</surname><given-names>MJ</given-names></name><name><surname>Hamiwka</surname><given-names>LD</given-names></name><name><surname>Wirrell</surname><given-names>EC</given-names></name></person-group>. <article-title>Cognitive and neurodevelopmental comorbidities in paediatric epilepsy</article-title>. <source/>Nat Rev Neurol. (<year>2016</year>) <volume>12</volume>:<fpage>465</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1038/nrneurol.2016.98</pub-id><pub-id pub-id-type="pmid">27448186</pub-id></mixed-citation>
</ref>
<ref id="B19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>IJff</surname><given-names>DM</given-names></name><name><surname>Postulart</surname><given-names>D</given-names></name><name><surname>Lambrechts</surname><given-names>D</given-names></name><name><surname>Majoie</surname><given-names>M</given-names></name><name><surname>de Kinderen</surname><given-names>R</given-names></name><name><surname>Hendriksen</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Cognitive and behavioral impact of the ketogenic diet in children and adolescents with refractory epilepsy: a randomized controlled trial</article-title>. <source/>Epilepsy Behav. (<year>2016</year>) <volume>60</volume>:<fpage>153</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.yebeh.2016.04.033</pub-id><pub-id pub-id-type="pmid">27206235</pub-id></mixed-citation>
</ref>
<ref id="B20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Berkel</surname><given-names>AA</given-names></name><name><surname>IJff</surname><given-names>DM</given-names></name><name><surname>Verkuyl</surname><given-names>JM</given-names></name></person-group>. <article-title>Cognitive benefits of the ketogenic diet in patients with epilepsy: a systematic overview</article-title>. <source/>Epilepsy Behav. (<year>2018</year>) <volume>87</volume>:<fpage>69</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1016/j.yebeh.2018.06.004</pub-id><pub-id pub-id-type="pmid">30173019</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Jia</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Hou</surname><given-names>Q</given-names></name><etal></etal></person-group>. <article-title>Ketogenic diet attenuates spatial and item memory impairment in pentylenetetrazol-kindled rats</article-title>. <source/>Brain Res. (<year>2016</year>) <volume>1646</volume>:<fpage>451</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainres.2016.06.029</pub-id><pub-id pub-id-type="pmid">27343950</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barwick</surname><given-names>K</given-names></name><name><surname>Parker</surname><given-names>T</given-names></name><name><surname>Murphy</surname><given-names>N</given-names></name><name><surname>Todd</surname><given-names>A</given-names></name><name><surname>Leveritt</surname><given-names>M</given-names></name><name><surname>Wilkinson</surname><given-names>SA</given-names></name></person-group>. <article-title>Development and pilot testing of a parent-reported health-related quality of life measure for children on the ketogenic diet: The KetoQoL</article-title>. <source/>Nutr Diet. (<year>2017</year>) <volume>74</volume>:<fpage>521</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/1747-0080.12348</pub-id><pub-id pub-id-type="pmid">29130289</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruce</surname><given-names>S</given-names></name><name><surname>Devlin</surname><given-names>A</given-names></name><name><surname>Air</surname><given-names>L</given-names></name><name><surname>Cook</surname><given-names>L</given-names></name></person-group>. <article-title>Changes in quality of life as a result of ketogenic diet therapy: a new approach to assessment with the potential for positive therapeutic effects</article-title>. <source/>Epilepsy Behav. (<year>2017</year>) <volume>66</volume>:<fpage>100</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.yebeh.2016.10.001</pub-id><pub-id pub-id-type="pmid">28038385</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>P</given-names></name><name><surname>Dingledine</surname><given-names>R</given-names></name><name><surname>Aronica</surname><given-names>E</given-names></name><name><surname>Bernard</surname><given-names>C</given-names></name><name><surname>Blumcke</surname><given-names>I</given-names></name><name><surname>Boison</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Commonalities in epileptogenic processes from different acute brain insults: do they translate?</article-title>
<source/>Epilepsia (<year>2018</year>) <volume>59</volume>:<fpage>37</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1111/epi.13965</pub-id><pub-id pub-id-type="pmid">29247482</pub-id></mixed-citation>
</ref>
<ref id="B25">
<label>25.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Sankhyan</surname><given-names>N</given-names></name><name><surname>Gulati</surname><given-names>S</given-names></name><name><surname>Agarwala</surname><given-names>A</given-names></name></person-group>. <article-title>Use of the modified Atkins diet for treatment of refractory childhood epilepsy: a randomized controlled trial</article-title>. <source/>Epilepsia (<year>2013</year>) <volume>54</volume>:<fpage>481</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1111/epi.12069</pub-id><pub-id pub-id-type="pmid">23294191</pub-id></mixed-citation>
</ref>
<ref id="B26">
<label>26.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caraballo</surname><given-names>R</given-names></name><name><surname>Darra</surname><given-names>F</given-names></name><name><surname>Reyes</surname><given-names>G</given-names></name><name><surname>Armeno</surname><given-names>M</given-names></name><name><surname>Cresta</surname><given-names>A</given-names></name><name><surname>Mestre</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>The ketogenic diet in patients with myoclonic status in non-progressive encephalopathy</article-title>. <source/>Seizure (<year>2017</year>) <volume>51</volume>:<fpage>1</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.seizure.2017.07.002</pub-id><pub-id pub-id-type="pmid">28743048</pub-id></mixed-citation>
</ref>
<ref id="B27">
<label>27.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felton</surname><given-names>EA</given-names></name><name><surname>Cervenka</surname><given-names>MC</given-names></name></person-group>. <article-title>Dietary therapy is the best option for refractory nonsurgical epilepsy</article-title>. <source/>Epilepsia (<year>2015</year>) <volume>56</volume>:<fpage>1325</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/epi.13075</pub-id><pub-id pub-id-type="pmid">26198999</pub-id></mixed-citation>
</ref>
<ref id="B28">
<label>28.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dressler</surname><given-names>A</given-names></name><name><surname>Stocklin</surname><given-names>B</given-names></name><name><surname>Reithofer</surname><given-names>E</given-names></name><name><surname>Benninger</surname><given-names>F</given-names></name><name><surname>Freilinger</surname><given-names>M</given-names></name><name><surname>Hauser</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>Long-term outcome and tolerability of the ketogenic diet in drug-resistant childhood epilepsy–the Austrian experience</article-title>. <source/>Seizure (<year>2010</year>) <volume>19</volume>:<fpage>404</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.seizure.2010.06.006</pub-id><pub-id pub-id-type="pmid">20598586</pub-id></mixed-citation>
</ref>
<ref id="B29">
<label>29.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boison</surname><given-names>D</given-names></name></person-group>. <article-title>New insights into the mechanisms of the ketogenic diet</article-title>. <source/>Curr Opin Neurol. (<year>2017</year>) <volume>30</volume>:<fpage>187</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1097/WCO.0000000000000432</pub-id><pub-id pub-id-type="pmid">28141738</pub-id></mixed-citation>
</ref>
<ref id="B30">
<label>30.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El</surname><given-names>YM</given-names></name><name><surname>Ledent</surname><given-names>C</given-names></name><name><surname>Parmentier</surname><given-names>M</given-names></name><name><surname>Costentin</surname><given-names>J</given-names></name><name><surname>Vaugeois</surname><given-names>JM</given-names></name></person-group>
<article-title>Evidence for the involvement of the adenosine A(2A) receptor in the lowered susceptibility to pentylenetetrazol-induced seizures produced in mice by long-term treatment with caffeine</article-title>. <source/>Neuropharmacology (<year>2008</year>) <volume>55</volume>:<fpage>35</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2008.04.007</pub-id><pub-id pub-id-type="pmid">18486156</pub-id></mixed-citation>
</ref>
<ref id="B31">
<label>31.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curia</surname><given-names>G</given-names></name><name><surname>Longo</surname><given-names>D</given-names></name><name><surname>Biagini</surname><given-names>G</given-names></name><name><surname>Jones</surname><given-names>RS</given-names></name><name><surname>Avoli</surname><given-names>M</given-names></name></person-group>. <article-title>The pilocarpine model of temporal lobe epilepsy</article-title>. <source/>J Neurosci Methods (<year>2008</year>) <volume>172</volume>:<fpage>143</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jneumeth.2008.04.019</pub-id><pub-id pub-id-type="pmid">18550176</pub-id></mixed-citation>
</ref>
<ref id="B32">
<label>32.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boison</surname><given-names>D</given-names></name><name><surname>Steinhauser</surname><given-names>C</given-names></name></person-group>. <article-title>Epilepsy and astrocyte energy metabolism</article-title>. <source/>GLIA (<year>2018</year>) <volume>66</volume>:<fpage>1235</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1002/glia.23247</pub-id><pub-id pub-id-type="pmid">29044647</pub-id></mixed-citation>
</ref>
<ref id="B33">
<label>33.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simeone</surname><given-names>KA</given-names></name><name><surname>Matthews</surname><given-names>SA</given-names></name><name><surname>Rho</surname><given-names>JM</given-names></name><name><surname>Simeone</surname><given-names>TA</given-names></name></person-group>. <article-title>Ketogenic diet treatment increases longevity in Kcna1-null mice, a model of sudden unexpected death in epilepsy</article-title>. <source/>Epilepsia (<year>2016</year>) <volume>57</volume>:<fpage>e178</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1111/epi.13444</pub-id><pub-id pub-id-type="pmid">27346881</pub-id></mixed-citation>
</ref>
<ref id="B34">
<label>34.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ryvlin</surname><given-names>P</given-names></name><name><surname>Nashef</surname><given-names>L</given-names></name><name><surname>Lhatoo</surname><given-names>SD</given-names></name><name><surname>Bateman</surname><given-names>LM</given-names></name><name><surname>Bird</surname><given-names>J</given-names></name><name><surname>Bleasel</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study</article-title>. <source/>Lancet Neurol. (<year>2013</year>) <volume>12</volume>:<fpage>966</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(13)70214-X</pub-id><pub-id pub-id-type="pmid">24012372</pub-id></mixed-citation>
</ref>
<ref id="B35">
<label>35.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simeone</surname><given-names>TA</given-names></name><name><surname>Samson</surname><given-names>KK</given-names></name><name><surname>Matthews</surname><given-names>SA</given-names></name><name><surname>Simeone</surname><given-names>KA</given-names></name></person-group>. <article-title><italic>In vivo</italic> ketogenic diet treatment attenuates pathologic sharp waves and high frequency oscillations in <italic>in vitro</italic> hippocampal slices from epileptic Kv 1.1alpha knockout mice</article-title>. <source/>Epilepsia (<year>2014</year>) <volume>55</volume>: <fpage>e44</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/epi.12603</pub-id><pub-id pub-id-type="pmid">24702645</pub-id></mixed-citation>
</ref>
<ref id="B36">
<label>36.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DY</given-names></name><name><surname>Simeone</surname><given-names>KA</given-names></name><name><surname>Simeone</surname><given-names>TA</given-names></name><name><surname>Pandya</surname><given-names>JD</given-names></name><name><surname>Wilke</surname><given-names>JC</given-names></name><name><surname>Ahn</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Ketone bodies mediate antiseizure effects through mitochondrial permeability transition</article-title>. <source/>Ann Neurol. (<year>2015</year>) <volume>78</volume>:<fpage>77</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1002/ana.24424</pub-id><pub-id pub-id-type="pmid">25899847</pub-id></mixed-citation>
</ref>
<ref id="B37">
<label>37.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simeone</surname><given-names>KA</given-names></name><name><surname>Hallgren</surname><given-names>J</given-names></name><name><surname>Bockman</surname><given-names>CS</given-names></name><name><surname>Aggarwal</surname><given-names>A</given-names></name><name><surname>Kansal</surname><given-names>V</given-names></name><name><surname>Netzel</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Respiratory dysfunction progresses with age in Kcna1-null mice, a model of sudden unexpected death in epilepsy</article-title>. <source/>Epilepsia (<year>2018</year>) <volume>59</volume>:<fpage>345</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1111/epi.13971</pub-id><pub-id pub-id-type="pmid">29327348</pub-id></mixed-citation>
</ref>
<ref id="B38">
<label>38.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>BM</given-names></name><name><surname>Jerry</surname><given-names>JC</given-names></name><name><surname>Tatalovic</surname><given-names>M</given-names></name><name><surname>Kaufman</surname><given-names>ES</given-names></name><name><surname>Kline</surname><given-names>DD</given-names></name><name><surname>Kunze</surname><given-names>DL</given-names></name></person-group>. <article-title>The Kv1</article-title>.1 null mouse, a model of sudden unexpected death in epilepsy (SUDEP). <source/>Epilepsia (<year>2014</year>) <volume>55</volume>:<fpage>1808</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1111/epi.12793</pub-id><pub-id pub-id-type="pmid">25377007</pub-id></mixed-citation>
</ref>
<ref id="B39">
<label>39.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitkanen</surname><given-names>A</given-names></name><name><surname>McIntosh</surname><given-names>TK</given-names></name></person-group>. <article-title>Animal models of post-traumatic epilepsy</article-title>. <source/>J Neurotrauma. (<year>2006</year>) <volume>23</volume>:<fpage>241</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1089/neu.2006.23.241</pub-id><pub-id pub-id-type="pmid">16503807</pub-id></mixed-citation>
</ref>
<ref id="B40">
<label>40.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwartzkroin</surname><given-names>PA</given-names></name><name><surname>Wenzel</surname><given-names>HJ</given-names></name><name><surname>Lyeth</surname><given-names>BG</given-names></name><name><surname>Poon</surname><given-names>CC</given-names></name><name><surname>Delance</surname><given-names>A</given-names></name><name><surname>Van</surname><given-names>KC</given-names></name><etal></etal></person-group>. <article-title>Does ketogenic diet alter seizure sensitivity and cell loss following fluid percussion injury?</article-title>
<source/>Epilepsy Res. (<year>2010</year>) <volume>92</volume>:<fpage>74</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.eplepsyres.2010.08.009</pub-id><pub-id pub-id-type="pmid">20863664</pub-id></mixed-citation>
</ref>
<ref id="B41">
<label>41.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linard</surname><given-names>B</given-names></name><name><surname>Ferrandon</surname><given-names>A</given-names></name><name><surname>Koning</surname><given-names>E</given-names></name><name><surname>Nehlig</surname><given-names>A</given-names></name><name><surname>Raffo</surname><given-names>E</given-names></name></person-group>. <article-title>Ketogenic diet exhibits neuroprotective effects in hippocampus but fails to prevent epileptogenesis in the lithium-pilocarpine model of mesial temporal lobe epilepsy in adult rats</article-title>. <source/>Epilepsia (<year>2010</year>) <volume>51</volume>:<fpage>1829</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1111/j.1528-1167.2010.02667.x</pub-id><pub-id pub-id-type="pmid">20633040</pub-id></mixed-citation>
</ref>
<ref id="B42">
<label>42.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin-McGill</surname><given-names>KJ</given-names></name><name><surname>Jackson</surname><given-names>CF</given-names></name><name><surname>Bresnahan</surname><given-names>R</given-names></name><name><surname>Levy</surname><given-names>RG</given-names></name><name><surname>Cooper</surname><given-names>PN</given-names></name></person-group>. <article-title>Ketogenic diets for drug-resistant epilepsy</article-title>. <source/>Cochrane Database Syst Rev. (<year>2018</year>) <volume>11</volume>:<fpage>D1903</fpage>. <pub-id pub-id-type="doi">10.1002/14651858.CD001903.pub4</pub-id><pub-id pub-id-type="pmid">30403286</pub-id></mixed-citation>
</ref>
<ref id="B43">
<label>43.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lambrechts</surname><given-names>D</given-names></name><name><surname>de Kinderen</surname><given-names>R</given-names></name><name><surname>Vles</surname><given-names>J</given-names></name><name><surname>de Louw</surname><given-names>A</given-names></name><name><surname>Aldenkamp</surname><given-names>AP</given-names></name><name><surname>Majoie</surname><given-names>H</given-names></name></person-group>. <article-title>A randomized controlled trial of the ketogenic diet in refractory childhood epilepsy</article-title>. <source/>ACTA Neurol Scand. (<year>2018</year>) <volume>137</volume>:<fpage>152</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1111/ane.12802</pub-id><pub-id pub-id-type="pmid">29205273</pub-id></mixed-citation>
</ref>
<ref id="B44">
<label>44.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Rashidy</surname><given-names>OF</given-names></name><name><surname>Nassar</surname><given-names>MF</given-names></name><name><surname>Abdel-Hamid</surname><given-names>IA</given-names></name><name><surname>Shatla</surname><given-names>RH</given-names></name><name><surname>Abdel-Hamid</surname><given-names>MH</given-names></name><name><surname>Gabr</surname><given-names>SS</given-names></name><etal></etal></person-group>. <article-title>Modified Atkins diet vs classic ketogenic formula in intractable epilepsy</article-title>. <source/>ACTA Neurol Scand. (<year>2013</year>) <volume>128</volume>:<fpage>402</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/ane.12137</pub-id><pub-id pub-id-type="pmid">23679058</pub-id></mixed-citation>
</ref>
<ref id="B45">
<label>45.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>JA</given-names></name><name><surname>Yoon</surname><given-names>JR</given-names></name><name><surname>Lee</surname><given-names>EJ</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>JT</given-names></name><name><surname>Kim</surname><given-names>HD</given-names></name><etal></etal></person-group>. <article-title>Efficacy of the classic ketogenic and the modified Atkins diets in refractory childhood epilepsy</article-title>. <source/>Epilepsia (<year>2016</year>) <volume>57</volume>:<fpage>51</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/epi.13256</pub-id><pub-id pub-id-type="pmid">26662710</pub-id></mixed-citation>
</ref>
<ref id="B46">
<label>46.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raju</surname><given-names>KN</given-names></name><name><surname>Gulati</surname><given-names>S</given-names></name><name><surname>Kabra</surname><given-names>M</given-names></name><name><surname>Agarwala</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Pandey</surname><given-names>RM</given-names></name><etal></etal></person-group>. <article-title>Efficacy of 4:1 (classic) versus 2</article-title>.5:1 ketogenic ratio diets in refractory epilepsy in young children: a randomized open labeled study. <source/>Epilepsy Res. (<year>2011</year>) <volume>96</volume>:<fpage>96</fpage>–<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1016/j.eplepsyres.2011.05.005</pub-id><pub-id pub-id-type="pmid">21621394</pub-id></mixed-citation>
</ref>
<ref id="B47">
<label>47.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luan</surname><given-names>G</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Zhai</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Adenosine kinase expression in cortical dysplasia with balloon cells: analysis of developmental lineage of cell types</article-title>. <source/>J Neuropathol Exp Neurol. (<year>2015</year>) <volume>74</volume>:<fpage>132</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1097/NEN.0000000000000156</pub-id><pub-id pub-id-type="pmid">25575137</pub-id></mixed-citation>
</ref>
<ref id="B48">
<label>48.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Ren</surname><given-names>G</given-names></name><name><surname>Lusardi</surname><given-names>T</given-names></name><name><surname>Wilz</surname><given-names>A</given-names></name><name><surname>Lan</surname><given-names>JQ</given-names></name><name><surname>Iwasato</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Adenosine kinase is a target for the prediction and prevention of epileptogenesis in mice</article-title>. <source/>J Clin Invest. (<year>2008</year>) <volume>118</volume>:<fpage>571</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1172/JCI33737</pub-id><pub-id pub-id-type="pmid">18172552</pub-id></mixed-citation>
</ref>
<ref id="B49">
<label>49.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Steinbeck</surname><given-names>JA</given-names></name><name><surname>Lusardi</surname><given-names>T</given-names></name><name><surname>Koch</surname><given-names>P</given-names></name><name><surname>Lan</surname><given-names>JQ</given-names></name><name><surname>Wilz</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Suppression of kindling epileptogenesis by adenosine releasing stem cell-derived brain implants</article-title>. <source/>Brain (<year>2007</year>) <volume>130</volume>:<fpage>1276</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awm057</pub-id><pub-id pub-id-type="pmid">17472985</pub-id></mixed-citation>
</ref>
<ref id="B50">
<label>50.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Lytle</surname><given-names>N</given-names></name><name><surname>Lan</surname><given-names>JQ</given-names></name><name><surname>Sandau</surname><given-names>US</given-names></name><name><surname>Boison</surname><given-names>D</given-names></name></person-group>. <article-title>Local disruption of glial adenosine homeostasis in mice associates with focal electrographic seizures: a first step in epileptogenesis?</article-title>
<source/>GLIA (<year>2012</year>) <volume>60</volume>:<fpage>83</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1002/glia.21250</pub-id><pub-id pub-id-type="pmid">21964979</pub-id></mixed-citation>
</ref>
<ref id="B51">
<label>51.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams-Karnesky</surname><given-names>RL</given-names></name><name><surname>Sandau</surname><given-names>US</given-names></name><name><surname>Lusardi</surname><given-names>TA</given-names></name><name><surname>Lytle</surname><given-names>NK</given-names></name><name><surname>Farrell</surname><given-names>JM</given-names></name><name><surname>Pritchard</surname><given-names>EM</given-names></name><etal></etal></person-group>. <article-title>Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis</article-title>. <source/>J Clin Invest. (<year>2013</year>) <volume>123</volume>:<fpage>3552</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1172/JCI65636</pub-id><pub-id pub-id-type="pmid">23863710</pub-id></mixed-citation>
</ref>
<ref id="B52">
<label>52.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luan</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Deng</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Upregulation of neuronal adenosine A1 receptor in human rasmussen encephalitis</article-title>. <source/>J Neuropathol Exp Neurol. (<year>2017</year>) <volume>76</volume>:<fpage>720</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1093/jnen/nlx053</pub-id><pub-id pub-id-type="pmid">28789481</pub-id></mixed-citation>
</ref>
<ref id="B53">
<label>53.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luan</surname><given-names>G</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Zhai</surname><given-names>F</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Upregulation of adenosine kinase in Rasmussen encephalitis</article-title>. <source/>J Neuropathol Exp Neurol. (<year>2013</year>) <volume>72</volume>:<fpage>1000</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1097/01.jnen.0000435369.39388.5c</pub-id><pub-id pub-id-type="pmid">24128682</pub-id></mixed-citation>
</ref>
<ref id="B54">
<label>54.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borea</surname><given-names>PA</given-names></name><name><surname>Gessi</surname><given-names>S</given-names></name><name><surname>Merighi</surname><given-names>S</given-names></name><name><surname>Varani</surname><given-names>K</given-names></name></person-group>. <article-title>Adenosine as a multi-signalling guardian angel in human diseases: when, where and how does it exert its protective effects?</article-title>
<source/>Trends Pharmacol Sci. (<year>2016</year>) <volume>37</volume>:<fpage>419</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2016.02.006</pub-id><pub-id pub-id-type="pmid">26944097</pub-id></mixed-citation>
</ref>
<ref id="B55">
<label>55.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Quan</surname><given-names>LJ</given-names></name><name><surname>Fredholm</surname><given-names>BB</given-names></name><name><surname>Simon</surname><given-names>RP</given-names></name><name><surname>Boison</surname><given-names>D</given-names></name></person-group>. <article-title>Adenosine dysfunction in astrogliosis: cause for seizure generation?</article-title>
<source/>Neuron Glia Biol. (<year>2007</year>) <volume>3</volume>:<fpage>353</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1017/S1740925X0800015X</pub-id><pub-id pub-id-type="pmid">18634566</pub-id></mixed-citation>
</ref>
<ref id="B56">
<label>56.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Ren</surname><given-names>G</given-names></name><name><surname>Kaplan</surname><given-names>DL</given-names></name><name><surname>Boison</surname><given-names>D</given-names></name></person-group>. <article-title>Human mesenchymal stem cell grafts engineered to release adenosine reduce chronic seizures in a mouse model of CA3-selective epileptogenesis</article-title>. <source/>Epilepsy Res. (<year>2009</year>) <volume>84</volume>:<fpage>238</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.eplepsyres.2009.01.002</pub-id><pub-id pub-id-type="pmid">19217263</pub-id></mixed-citation>
</ref>
<ref id="B57">
<label>57.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilz</surname><given-names>A</given-names></name><name><surname>Pritchard</surname><given-names>EM</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Lan</surname><given-names>JQ</given-names></name><name><surname>Kaplan</surname><given-names>DL</given-names></name><name><surname>Boison</surname><given-names>D</given-names></name></person-group>. <article-title>Silk polymer-based adenosine release: therapeutic potential for epilepsy</article-title>. <source/>Biomaterials (<year>2008</year>) <volume>29</volume>:<fpage>3609</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2008.05.010</pub-id><pub-id pub-id-type="pmid">18514814</pub-id></mixed-citation>
</ref>
<ref id="B58">
<label>58.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reppert</surname><given-names>SM</given-names></name><name><surname>Weaver</surname><given-names>DR</given-names></name><name><surname>Stehle</surname><given-names>JH</given-names></name><name><surname>Rivkees</surname><given-names>SA</given-names></name></person-group>. <article-title>Molecular cloning and characterization of a rat A1-adenosine receptor that is widely expressed in brain and spinal cord</article-title>. <source/>Mol Endocrinol. (<year>1991</year>) <volume>5</volume>:<fpage>1037</fpage>–<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1210/mend-5-8-1037</pub-id><pub-id pub-id-type="pmid">1658635</pub-id></mixed-citation>
</ref>
<ref id="B59">
<label>59.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wardas</surname><given-names>J</given-names></name></person-group>. <article-title>Neuroprotective role of adenosine in the CNS</article-title>. <source/>Pol J Pharmacol. (<year>2002</year>) <volume>54</volume>:<fpage>313</fpage>–<lpage>26</lpage>. Available online at: <ext-link ext-link-type="uri" xlink:href="http://www.if-pan.krakow.pl/pjp/pdf/2002/4_313.pdf">http://www.if-pan.krakow.pl/pjp/pdf/2002/4_313.pdf</ext-link><pub-id pub-id-type="pmid">12523485</pub-id></mixed-citation>
</ref>
<ref id="B60">
<label>60.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boison</surname><given-names>D</given-names></name></person-group>. <article-title>Adenosinergic signaling in epilepsy</article-title>. <source/>Neuropharmacology (<year>2016</year>) <volume>104</volume>:<fpage>131</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.08.046</pub-id><pub-id pub-id-type="pmid">26341819</pub-id></mixed-citation>
</ref>
<ref id="B61">
<label>61.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobow</surname><given-names>K</given-names></name><name><surname>Blumcke</surname><given-names>I</given-names></name></person-group>. <article-title>The emerging role of DNA methylation in epileptogenesis</article-title>. <source/>Epilepsia (<year>2012</year>) <volume>53</volume>:<fpage>11</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1111/epi.12031</pub-id><pub-id pub-id-type="pmid">23216575</pub-id></mixed-citation>
</ref>
<ref id="B62">
<label>62.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Younus</surname><given-names>I</given-names></name><name><surname>Reddy</surname><given-names>DS</given-names></name></person-group>. <article-title>Epigenetic interventions for epileptogenesis: A new frontier for curing epilepsy</article-title>. <source/>Pharmacol Ther. (<year>2017</year>) <volume>177</volume>:<fpage>108</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2017.03.002</pub-id><pub-id pub-id-type="pmid">28279785</pub-id></mixed-citation>
</ref>
<ref id="B63">
<label>63.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal></etal></person-group>. <article-title>RASgrf1, a Potential Methylatic Mediator of Anti-epileptogenesis?</article-title>
<source/>Neurochem Res. (<year>2018</year>) <volume>43</volume>:<fpage>2000</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1007/s11064-018-2621-9</pub-id><pub-id pub-id-type="pmid">30242550</pub-id></mixed-citation>
</ref>
<ref id="B64">
<label>64.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feinstein</surname><given-names>AR</given-names></name></person-group>. <article-title>The pre-therapeutic classification of co-morbidity in chronic disease</article-title>. <source/>J Chronic Dis. (<year>1970</year>) <volume>23</volume>:<fpage>455</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/0021-9681(70)90054-8</pub-id><pub-id pub-id-type="pmid">26309916</pub-id></mixed-citation>
</ref>
<ref id="B65">
<label>65.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Novy</surname><given-names>J</given-names></name><name><surname>Bell</surname><given-names>GS</given-names></name><name><surname>Peacock</surname><given-names>JL</given-names></name><name><surname>Sisodiya</surname><given-names>SM</given-names></name><name><surname>Sander</surname><given-names>JW</given-names></name></person-group>. <article-title>Epilepsy as a systemic condition: link with somatic comorbidities</article-title>. <source/>Acta Neurol Scand. (<year>2017</year>) <volume>136</volume>:<fpage>352</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/ane.12779</pub-id><pub-id pub-id-type="pmid">28573736</pub-id></mixed-citation>
</ref>
<ref id="B66">
<label>66.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name></person-group>
<article-title>Epilepsy and associated comorbidities</article-title>. <source/>Neuropsychiatry(Lond) (<year>2017</year>) <volume>1</volume>:<fpage>1</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.4172/Neuropsychiatry.1000e101</pub-id></mixed-citation>
</ref>
<ref id="B67">
<label>67.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stafstrom</surname><given-names>CE</given-names></name></person-group>. <article-title>Issues in clinical epileptology: a view from the bench. a festschrift in honor of philip a. schwartzkroin, PhD</article-title>. <source/>Epilepsy Curr. (<year>2013</year>) <volume>13</volume>:<fpage>291</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.5698/1535-7597-13.6.291</pub-id><pub-id pub-id-type="pmid">24348132</pub-id></mixed-citation>
</ref>
<ref id="B68">
<label>68.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaitatzis</surname><given-names>A</given-names></name><name><surname>Carroll</surname><given-names>K</given-names></name><name><surname>Majeed</surname><given-names>A WSJ</given-names></name></person-group>. <article-title>The epidemiology of the comorbidity of epilepsy in the general population</article-title>. <source/>Epilepsia (<year>2004</year>) <volume>45</volume>:<fpage>1613</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1111/j.0013-9580.2004.17504.x</pub-id><pub-id pub-id-type="pmid">15571520</pub-id></mixed-citation>
</ref>
<ref id="B69">
<label>69.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mutlu</surname><given-names>A</given-names></name></person-group>
<article-title>Association between epilepsy and headache</article-title>. <source/>Neurol Sci. (<year>2018</year>) <volume>39</volume>:<fpage>2129</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1007/s10072-018-3558-0</pub-id></mixed-citation>
</ref>
<ref id="B70">
<label>70.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Latreille</surname><given-names>V</given-names></name><name><surname>St</surname><given-names>LE</given-names></name><name><surname>Pavlova</surname><given-names>M</given-names></name></person-group>. <article-title>Co-morbid sleep disorders and epilepsy: a narrative review and case examples</article-title>. <source/>Epilepsy Res. (<year>2018</year>) <volume>145</volume>:<fpage>185</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1016/j.eplepsyres.2018.07.005</pub-id><pub-id pub-id-type="pmid">30048932</pub-id></mixed-citation>
</ref>
<ref id="B71">
<label>71.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ottman</surname><given-names>R</given-names></name><name><surname>Lipton</surname><given-names>RB</given-names></name><name><surname>Ettinger</surname><given-names>AB</given-names></name><name><surname>Cramer</surname><given-names>JA</given-names></name><name><surname>Reed</surname><given-names>ML</given-names></name><name><surname>Morrison</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Comorbidities of epilepsy: results from the Epilepsy Comorbidities and Health (EPIC) survey</article-title>. <source/>Epilepsia (<year>2011</year>) <volume>52</volume>:<fpage>308</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1111/j.1528-1167.2010.02927.x</pub-id><pub-id pub-id-type="pmid">21269285</pub-id></mixed-citation>
</ref>
<ref id="B72">
<label>72.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>U</given-names></name><name><surname>Medel-Matus</surname><given-names>JS</given-names></name><name><surname>Redwine</surname><given-names>HM</given-names></name><name><surname>Shin</surname><given-names>D</given-names></name><name><surname>Hensler</surname><given-names>JG</given-names></name><name><surname>Sankar</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>Effects of selective serotonin and norepinephrine reuptake inhibitors on depressive- and impulsive-like behaviors and on monoamine transmission in experimental temporal lobe epilepsy</article-title>. <source/>Epilepsia (<year>2016</year>) <volume>57</volume>:<fpage>506</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1111/epi.13321</pub-id><pub-id pub-id-type="pmid">26813337</pub-id></mixed-citation>
</ref>
<ref id="B73">
<label>73.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medel-Matus</surname><given-names>JS</given-names></name><name><surname>Shin</surname><given-names>D</given-names></name><name><surname>Sankar</surname><given-names>R</given-names></name><name><surname>Mazarati</surname><given-names>A</given-names></name></person-group>. <article-title>Kindling epileptogenesis and panic-like behavior: their bidirectional connection and contribution to epilepsy-associated depression</article-title>. <source/>Epilepsy Behav. (<year>2017</year>) <volume>77</volume>:<fpage>33</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.yebeh.2017.10.001</pub-id><pub-id pub-id-type="pmid">29107199</pub-id></mixed-citation>
</ref>
<ref id="B74">
<label>74.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguilar</surname><given-names>BL</given-names></name><name><surname>Malkova</surname><given-names>L</given-names></name><name><surname>N'Gouemo</surname><given-names>P</given-names></name><name><surname>Forcelli</surname><given-names>PA</given-names></name></person-group>. <article-title>Genetically epilepsy-prone rats display anxiety-like behaviors and neuropsychiatric comorbidities of epilepsy</article-title>. <source/>Front Neurol. (<year>2018</year>) <volume>9</volume>:<fpage>476</fpage>. <pub-id pub-id-type="doi">10.3389/fneur.2018.00476</pub-id><pub-id pub-id-type="pmid">29997563</pub-id></mixed-citation>
</ref>
<ref id="B75">
<label>75.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medel-Matus</surname><given-names>JS</given-names></name><name><surname>Shin</surname><given-names>D</given-names></name><name><surname>Sankar</surname><given-names>R</given-names></name><name><surname>Mazarati</surname><given-names>A</given-names></name></person-group>. <article-title>Galanin contributes to monoaminergic dysfunction and to dependent neurobehavioral comorbidities of epilepsy</article-title>. <source/>Exp Neurol. (<year>2017</year>) <volume>289</volume>:<fpage>64</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.expneurol.2016.12.008</pub-id><pub-id pub-id-type="pmid">28013000</pub-id></mixed-citation>
</ref>
<ref id="B76">
<label>76.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>SJ</given-names></name><name><surname>Baxendale</surname><given-names>S</given-names></name></person-group>. <article-title>Reprint of: The new approach to classification: rethinking cognition and behavior in epilepsy</article-title>. <source/>Epilepsy Behav. (<year>2016</year>) <volume>64</volume>:<fpage>300</fpage>–<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/j.yebeh.2016.11.024</pub-id><pub-id pub-id-type="pmid">27876292</pub-id></mixed-citation>
</ref>
<ref id="B77">
<label>77.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermann</surname><given-names>BP</given-names></name><name><surname>Dabbs</surname><given-names>K</given-names></name><name><surname>Becker</surname><given-names>T</given-names></name><name><surname>Jones</surname><given-names>JE</given-names></name><name><surname>Myers</surname><given-names>YGA</given-names></name><name><surname>Wendt</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>Brain development in children with new onset epilepsy: a prospective controlled cohort investigation</article-title>. <source/>Epilepsia (<year>2010</year>) <volume>51</volume>:<fpage>2038</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1111/j.1528-1167.2010.02563.x</pub-id><pub-id pub-id-type="pmid">20384719</pub-id></mixed-citation>
</ref>
<ref id="B78">
<label>78.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermann</surname><given-names>B</given-names></name><name><surname>Jones</surname><given-names>J</given-names></name><name><surname>Dabbs</surname><given-names>K</given-names></name><name><surname>Allen</surname><given-names>CA</given-names></name><name><surname>Sheth</surname><given-names>R</given-names></name><name><surname>Fine</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>The frequency, complications and aetiology of ADHD in new onset paediatric epilepsy</article-title>. <source/>Brain (<year>2007</year>) <volume>130</volume>:<fpage>3135</fpage>–<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awm227</pub-id><pub-id pub-id-type="pmid">17947336</pub-id></mixed-citation>
</ref>
<ref id="B79">
<label>79.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hermann</surname><given-names>B</given-names></name><name><surname>Jones</surname><given-names>J</given-names></name><name><surname>Sheth</surname><given-names>R</given-names></name><name><surname>Dow</surname><given-names>C</given-names></name><name><surname>Koehn</surname><given-names>M</given-names></name><name><surname>Seidenberg</surname><given-names>M</given-names></name></person-group>. <article-title>Children with new-onset epilepsy: neuropsychological status and brain structure</article-title>. <source/>Brain (<year>2006</year>) <volume>129</volume>:<fpage>2609</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1093/brain/awl196</pub-id><pub-id pub-id-type="pmid">16928696</pub-id></mixed-citation>
</ref>
<ref id="B80">
<label>80.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salpekar</surname><given-names>JA</given-names></name><name><surname>Mula</surname><given-names>M</given-names></name></person-group>. <article-title>Common psychiatric comorbidities in epilepsy: how big of a problem is it?</article-title>
<source/>Epilepsy Behav. (<year>2018</year>). <pub-id pub-id-type="doi">10.1016/j.yebeh.2018.07.023</pub-id><pub-id pub-id-type="pmid">30149996</pub-id></mixed-citation>
</ref>
<ref id="B81">
<label>81.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanner</surname><given-names>AM</given-names></name></person-group>. <article-title>Management of psychiatric and neurological comorbidities in epilepsy</article-title>. <source/>Nat Rev Neurol. (<year>2016</year>) <volume>12</volume>:<fpage>106</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1038/nrneurol.2015.243</pub-id><pub-id pub-id-type="pmid">26782334</pub-id></mixed-citation>
</ref>
<ref id="B82">
<label>82.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Penas</surname><given-names>JJ</given-names></name></person-group>. <article-title>[Epilepsy, cognition and ketogenic diet]</article-title>. <source/>Rev Neurol. (<year>2018</year>) <volume>66</volume>:<fpage>S71</fpage>–<lpage>5</lpage>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.neurologia.com/articulo/2017529">https://www.neurologia.com/articulo/2017529</ext-link><pub-id pub-id-type="pmid">29516456</pub-id></mixed-citation>
</ref>
<ref id="B83">
<label>83.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>T</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Ketogenic diet improves the spatial memory impairment caused by exposure to hypobaric hypoxia through increased acetylation of histones in rats</article-title>. <source/>PLoS ONE (<year>2017</year>) 12:e174477. <pub-id pub-id-type="doi">10.1371/journal.pone.0174477</pub-id><pub-id pub-id-type="pmid">28355243</pub-id></mixed-citation>
</ref>
<ref id="B84">
<label>84.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia-Penas</surname><given-names>JJ</given-names></name></person-group>. <article-title>Epilepsy, cognition and ketogenic diet</article-title>. <source/>Rev Neurol. (<year>2018</year>) <volume>66</volume>: <fpage>S71</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="pmid">29516456</pub-id></mixed-citation>
</ref>
<ref id="B85">
<label>85.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terrone</surname><given-names>G</given-names></name><name><surname>Pauletti</surname><given-names>A</given-names></name><name><surname>Salamone</surname><given-names>A</given-names></name><name><surname>Rizzi</surname><given-names>M</given-names></name><name><surname>Villa</surname><given-names>BR</given-names></name><name><surname>Porcu</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Inhibition of monoacylglycerol lipase terminates diazepam-resistant status epilepticus in mice and its effects are potentiated by a ketogenic diet</article-title>. <source/>Epilepsia (<year>2018</year>) <volume>59</volume>:<fpage>79</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1111/epi.13950</pub-id><pub-id pub-id-type="pmid">29171003</pub-id></mixed-citation>
</ref>
<ref id="B86">
<label>86.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>DJ</given-names></name><name><surname>Tian</surname><given-names>T</given-names></name></person-group>. <article-title>Ketogenic diet change cPLA2/clusterin and autophagy related gene expression and correlate with cognitive deficits and hippocampal MFs sprouting following neonatal seizures</article-title>. <source/>Epilepsy Res. (<year>2016</year>) <volume>120</volume>:<fpage>13</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.eplepsyres.2015.11.021</pub-id><pub-id pub-id-type="pmid">26709877</pub-id></mixed-citation>
</ref>
<ref id="B87">
<label>87.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bostock</surname><given-names>EC</given-names></name><name><surname>Kirkby</surname><given-names>KC</given-names></name><name><surname>Taylor</surname><given-names>BV</given-names></name></person-group>. <article-title>The current status of the ketogenic diet in psychiatry</article-title>. <source/>Front Psychiatry (<year>2017</year>) <volume>8</volume>:<fpage>43</fpage>. <pub-id pub-id-type="doi">10.3389/fpsyt.2017.00043</pub-id><pub-id pub-id-type="pmid">28373848</pub-id></mixed-citation>
</ref>
<ref id="B88">
<label>88.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brietzke</surname><given-names>E</given-names></name><name><surname>Mansur</surname><given-names>RB</given-names></name><name><surname>Subramaniapillai</surname><given-names>M</given-names></name><name><surname>Balanza-Martinez</surname><given-names>V</given-names></name><name><surname>Vinberg</surname><given-names>M</given-names></name><name><surname>Gonzalez-Pinto</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Ketogenic diet as a metabolic therapy for mood disorders: evidence and developments</article-title>. <source/>Neurosci Biobehav Rev. (<year>2018</year>) <volume>94</volume>:<fpage>11</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.neubiorev.2018.07.020</pub-id><pub-id pub-id-type="pmid">30075165</pub-id></mixed-citation>
</ref>
<ref id="B89">
<label>89.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Luan</surname><given-names>G</given-names></name></person-group>
<article-title>Adenosine dysfunction in Rasmussen's encephalitis</article-title>. <source/>Neuropsychiatry (London) (<year>2016</year>) <volume>6</volume>:<fpage>280</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.4172/neuropsychiatry.1000150</pub-id></mixed-citation>
</ref>
<ref id="B90">
<label>90.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boison</surname><given-names>D</given-names></name><name><surname>Aronica</surname><given-names>E</given-names></name></person-group>. <article-title>Comorbidities in neurology: is adenosine the common link?</article-title>
<source/>Neuropharmacology (<year>2015</year>) <volume>97</volume>:<fpage>18</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuropharm.2015.04.031</pub-id><pub-id pub-id-type="pmid">25979489</pub-id></mixed-citation>
</ref>
<ref id="B91">
<label>91.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matos</surname><given-names>M</given-names></name><name><surname>Shen</surname><given-names>HY</given-names></name><name><surname>Augusto</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>CJ</given-names></name><name><surname>Wang</surname><given-names>YT</given-names></name><etal></etal></person-group>. <article-title>Deletion of adenosine A2A receptors from astrocytes disrupts glutamate homeostasis leading to psychomotor and cognitive impairment: relevance to schizophrenia</article-title>. <source/>Biol Psychiatry (<year>2015</year>) <volume>78</volume>:<fpage>763</fpage>–<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2015.02.026</pub-id><pub-id pub-id-type="pmid">25869810</pub-id></mixed-citation>
</ref>
<ref id="B92">
<label>92.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>HY</given-names></name><name><surname>Singer</surname><given-names>P</given-names></name><name><surname>Lytle</surname><given-names>N</given-names></name><name><surname>Wei</surname><given-names>CJ</given-names></name><name><surname>Lan</surname><given-names>JQ</given-names></name><name><surname>Williams-Karnesky</surname><given-names>RL</given-names></name><etal></etal></person-group>. <article-title>Adenosine augmentation ameliorates psychotic and cognitive endophenotypes of schizophrenia</article-title>. <source/>J Clin Invest. (<year>2012</year>) <volume>122</volume>:<fpage>2567</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1172/JCI62378</pub-id><pub-id pub-id-type="pmid">22706302</pub-id></mixed-citation>
</ref>
<ref id="B93">
<label>93.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>D</given-names></name><name><surname>Spruill</surname><given-names>TM</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Tatsuoka</surname><given-names>C</given-names></name><name><surname>Stoll</surname><given-names>S</given-names></name><name><surname>Jobst</surname><given-names>BC</given-names></name><etal></etal></person-group>. <article-title>Depressive symptoms and suicidality among individuals with epilepsy enrolled in self-management studies: results from the US Centers for Disease Control and Prevention Managing Epilepsy Well (MEW) Network</article-title>. <source/>Epilepsy Behav. (<year>2018</year>) <volume>87</volume>:<fpage>235</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.yebeh.2018.06.024</pub-id><pub-id pub-id-type="pmid">30115600</pub-id></mixed-citation>
</ref>
<ref id="B94">
<label>94.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hines</surname><given-names>DJ</given-names></name><name><surname>Schmitt</surname><given-names>LI</given-names></name><name><surname>Hines</surname><given-names>RM</given-names></name><name><surname>Moss</surname><given-names>SJ</given-names></name><name><surname>Haydon</surname><given-names>PG</given-names></name></person-group>. <article-title>Antidepressant effects of sleep deprivation require astrocyte-dependent adenosine mediated signaling</article-title>. <source/>Transl Psychiatry (<year>2013</year>) 3:e212. <pub-id pub-id-type="doi">10.1038/tp.2012.136</pub-id><pub-id pub-id-type="pmid">23321809</pub-id></mixed-citation>
</ref>
<ref id="B95">
<label>95.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Berardis</surname><given-names>D</given-names></name><name><surname>Marini</surname><given-names>S</given-names></name><name><surname>Serroni</surname><given-names>N</given-names></name><name><surname>Rapini</surname><given-names>G</given-names></name><name><surname>Iasevoli</surname><given-names>F</given-names></name><name><surname>Valchera</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>S-Adenosyl-L-Methionine augmentation in patients with stage II treatment-resistant major depressive disorder: an open label, fixed dose, single-blind study</article-title>. <source/>ScientificWorldJournal (<year>2013</year>) <volume>2013</volume>:<fpage>204649</fpage>. <pub-id pub-id-type="doi">10.1155/2013/204649</pub-id><pub-id pub-id-type="pmid">23766680</pub-id></mixed-citation>
</ref>
<ref id="B96">
<label>96.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Georgoudis</surname><given-names>G</given-names></name><name><surname>Felah</surname><given-names>B</given-names></name><name><surname>Nikolaidis</surname><given-names>PT</given-names></name><name><surname>Papandreou</surname><given-names>M</given-names></name><name><surname>Mitsiokappa</surname><given-names>E</given-names></name><name><surname>Mavrogenis</surname><given-names>AF</given-names></name><etal></etal></person-group>. <article-title>The effect of physiotherapy and acupuncture on psychocognitive, somatic, quality of life, and disability characteristics in TTH patients</article-title>. <source/>J Pain Res. (<year>2018</year>) <volume>11</volume>:<fpage>2527</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.2147/JPR.S178110</pub-id><pub-id pub-id-type="pmid">30425565</pub-id></mixed-citation>
</ref>
<ref id="B97">
<label>97.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sallach</surname><given-names>K</given-names></name><name><surname>Leonhardt</surname><given-names>M</given-names></name></person-group>. <article-title>Acupuncture for treatment of depressive disorders in pain diseases</article-title>. <source/>Nervenarzt (<year>2018</year>) <volume>89</volume>:<fpage>986</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1007/s00115-018-0576-3</pub-id><pub-id pub-id-type="pmid">30076453</pub-id></mixed-citation>
</ref>
<ref id="B98">
<label>98.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drobisz</surname><given-names>D</given-names></name><name><surname>Damborska</surname><given-names>A</given-names></name></person-group>. <article-title>Deep brain stimulation targets for treating depression</article-title>. <source/>Behav Brain Res. (<year>2019</year>) <volume>359</volume>:<fpage>266</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2018.11.004</pub-id><pub-id pub-id-type="pmid">30414974</pub-id></mixed-citation>
</ref>
<ref id="B99">
<label>99.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bekar</surname><given-names>L</given-names></name><name><surname>Libionka</surname><given-names>W</given-names></name><name><surname>Tian</surname><given-names>GF</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Torres</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal></etal></person-group>. <article-title>Adenosine is crucial for deep brain stimulation-mediated attenuation of tremor</article-title>. <source/>Nat Med. (<year>2008</year>) <volume>14</volume>:<fpage>75</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1038/nm1693</pub-id><pub-id pub-id-type="pmid">18157140</pub-id></mixed-citation>
</ref>
<ref id="B100">
<label>100.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miranda</surname><given-names>MF</given-names></name><name><surname>Hamani</surname><given-names>C</given-names></name><name><surname>de Almeida</surname><given-names>AC</given-names></name><name><surname>Amorim</surname><given-names>BO</given-names></name><name><surname>Macedo</surname><given-names>CE</given-names></name><name><surname>Fernandes</surname><given-names>MJ</given-names></name><etal></etal></person-group>. <article-title>Role of adenosine in the antiepileptic effects of deep brain stimulation</article-title>. <source/>Front Cell Neurosci. (<year>2014</year>) <volume>8</volume>:<fpage>312</fpage>. <pub-id pub-id-type="doi">10.3389/fncel.2014.00312</pub-id><pub-id pub-id-type="pmid">25324724</pub-id></mixed-citation>
</ref>
<ref id="B101">
<label>101.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Peng</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><etal></etal></person-group>. <article-title>Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture</article-title>. <source/>Nat Neurosci. (<year>2010</year>) <volume>13</volume>:<fpage>883</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/nn.2562</pub-id><pub-id pub-id-type="pmid">20512135</pub-id></mixed-citation>
</ref>
<ref id="B102">
<label>102.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blutstein</surname><given-names>T</given-names></name><name><surname>Haydon</surname><given-names>PG</given-names></name></person-group>. <article-title>The Importance of astrocyte-derived purines in the modulation of sleep</article-title>. <source/>GLIA (<year>2013</year>) <volume>61</volume>:<fpage>129</fpage>–<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1002/glia.22422</pub-id><pub-id pub-id-type="pmid">23027687</pub-id></mixed-citation>
</ref>
<ref id="B103">
<label>103.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halassa</surname><given-names>MM</given-names></name><name><surname>Florian</surname><given-names>C</given-names></name><name><surname>Fellin</surname><given-names>T</given-names></name><name><surname>Munoz</surname><given-names>JR</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Abel</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Astrocytic modulation of sleep homeostasis and cognitive consequences of sleep loss</article-title>. <source/>Neuron (<year>2009</year>) <volume>61</volume>:<fpage>213</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2008.11.024</pub-id><pub-id pub-id-type="pmid">19186164</pub-id></mixed-citation>
</ref>
<ref id="B104">
<label>104.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benington</surname><given-names>JH</given-names></name><name><surname>Kodali</surname><given-names>SK</given-names></name><name><surname>Heller</surname><given-names>HC</given-names></name></person-group>. <article-title>Stimulation of A1 adenosine receptors mimics the electroencephalographic effects of sleep deprivation</article-title>. <source/>Brain Res. (<year>1995</year>) <volume>692</volume>:<fpage>79</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1016/0006-8993(95)00590-M</pub-id><pub-id pub-id-type="pmid">8548323</pub-id></mixed-citation>
</ref>
<ref id="B105">
<label>105.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Virus</surname><given-names>RM</given-names></name><name><surname>Ticho</surname><given-names>S</given-names></name><name><surname>Pilditch</surname><given-names>M</given-names></name><name><surname>Radulovacki</surname><given-names>M</given-names></name></person-group>. <article-title>A comparison of the effects of caffeine, 8-cyclopentyltheophylline, and alloxazine on sleep in rats</article-title>. possible roles of central nervous system adenosine receptors. <source/>Neuropsychopharmacol (<year>1990</year>) <volume>3</volume>:<fpage>243</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="pmid">2400543</pub-id></mixed-citation>
</ref>
<ref id="B106">
<label>106.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satoh</surname><given-names>S</given-names></name><name><surname>Matsumura</surname><given-names>H</given-names></name><name><surname>Hayaishi</surname><given-names>O</given-names></name></person-group>. <article-title>Involvement of adenosine A2A receptor in sleep promotion</article-title>. <source/>Eur J Pharmacol. (<year>1998</year>) <volume>351</volume>:<fpage>155</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/S0014-2999(98)00302-1</pub-id><pub-id pub-id-type="pmid">9686998</pub-id></mixed-citation>
</ref>
<ref id="B107">
<label>107.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scammell</surname><given-names>TE</given-names></name><name><surname>Gerashchenko</surname><given-names>DY</given-names></name><name><surname>Mochizuki</surname><given-names>T</given-names></name><name><surname>McCarthy</surname><given-names>MT</given-names></name><name><surname>Estabrooke</surname><given-names>IV</given-names></name><name><surname>Sears</surname><given-names>CA</given-names></name><etal></etal></person-group>. <article-title>An adenosine A2a agonist increases sleep and induces Fos in ventrolateral preoptic neurons</article-title>. <source/>Neuroscience (<year>2001</year>) <volume>107</volume>:<fpage>653</fpage>–<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1016/S0306-4522(01)00383-9</pub-id><pub-id pub-id-type="pmid">11720788</pub-id></mixed-citation>
</ref>
<ref id="B108">
<label>108.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urade</surname><given-names>Y</given-names></name><name><surname>Eguchi</surname><given-names>N</given-names></name><name><surname>Qu</surname><given-names>WM</given-names></name><name><surname>Sakata</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>ZL</given-names></name><name><surname>Chen</surname><given-names>JF</given-names></name><etal></etal></person-group>. <article-title>Sleep regulation in adenosine A2A receptor-deficient mice</article-title>. <source/>Neurology (<year>2003</year>) <volume>61</volume>:<fpage>S94</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1212/01.WNL.0000095222.41066.5E</pub-id><pub-id pub-id-type="pmid">14663019</pub-id></mixed-citation>
</ref>
<ref id="B109">
<label>109.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazarus</surname><given-names>M</given-names></name><name><surname>Shen</surname><given-names>HY</given-names></name><name><surname>Cherasse</surname><given-names>Y</given-names></name><name><surname>Qu</surname><given-names>WM</given-names></name><name><surname>Huang</surname><given-names>ZL</given-names></name><name><surname>Bass</surname><given-names>CE</given-names></name><etal></etal></person-group>. <article-title>Arousal effect of caffeine depends on adenosine A2A receptors in the shell of the nucleus accumbens</article-title>. <source/>J Neurosci. (<year>2011</year>) <volume>31</volume>:<fpage>10067</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.6730-10.2011</pub-id><pub-id pub-id-type="pmid">21734299</pub-id></mixed-citation>
</ref>
<ref id="B110">
<label>110.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>TJ</given-names></name><name><surname>Simeone</surname><given-names>TA</given-names></name><name><surname>Smith</surname><given-names>DD</given-names></name><name><surname>Grove</surname><given-names>R</given-names></name><name><surname>Adamec</surname><given-names>J</given-names></name><name><surname>Samson</surname><given-names>KK</given-names></name><etal></etal></person-group>. <article-title>Adenosine has two faces: regionally dichotomous adenosine tone in a model of epilepsy with comorbid sleep disorders</article-title>. <source/>Neurobiol Dis. (<year>2018</year>) <volume>114</volume>:<fpage>45</fpage>–<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1016/j.nbd.2018.01.017</pub-id><pub-id pub-id-type="pmid">29409952</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>